Format

Send to

Choose Destination
Biomaterials. 2019 Jul;210:1-11. doi: 10.1016/j.biomaterials.2019.04.017. Epub 2019 Apr 19.

Oxygen generating biomaterial improves the function and efficacy of beta cells within a macroencapsulation device.

Author information

1
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA.
2
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA; Interdisciplinary Program in Biomedical Sciences, University of Florida, Gainesville, FL, USA.
3
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA; University of Florida Diabetes Institute, Gainesville, FL, USA. Electronic address: cstabler@bme.ufl.edu.

Abstract

Tissue-engineered devices have the potential to significantly improve human health. A major impediment to the success of clinically scaled transplants, however, is insufficient oxygen transport, which leads to extensive cell death and dysfunction. To provide in situ supplementation of oxygen within a cellular implant, we developed a hydrolytically reactive oxygen generating material in the form of polydimethylsiloxane (PDMS) encapsulated solid calcium peroxide, termed OxySite. Herein, we demonstrate, for the first time, the successful implementation of this in situ oxygen-generating biomaterial to support elevated cellular function and efficacy of macroencapsulation devices for the treatment of type 1 diabetes. Under extreme hypoxic conditions, devices supplemented with OxySite exhibited substantially elevated beta cell and islet viability and function. Furthermore, the inclusion of OxySite within implanted macrodevices resulted in the significant improvement of graft efficacy and insulin production in a diabetic rodent model. Translating to human islets at elevated loading densities further validated the advantages of this material. This simple biomaterial-based approach for delivering a localized and controllable oxygen supply provides a broad and impactful platform for improving the therapeutic efficacy of cell-based approaches.

KEYWORDS:

Cell replacement therapy; Diabetes; Hypoxia; Islets; Tissue engineering

PMID:
31029812
PMCID:
PMC6527135
[Available on 2020-07-01]
DOI:
10.1016/j.biomaterials.2019.04.017

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center